Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial
Abstract Asthma is a common disease occurring worldwide. The clinical treatment of asthma is constantly revised and updated; however, it is associated with side effects. Our previous in vitro and ex vivo studies found that oligo-fucoidan can improve allergic immune responses and reduce airway inflam...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-21527-3 |
| _version_ | 1811197983014780928 |
|---|---|
| author | Chia-wei Yeh Chia-Ju Shih Tu-Chen Liu Ya-ling Chiou |
| author_facet | Chia-wei Yeh Chia-Ju Shih Tu-Chen Liu Ya-ling Chiou |
| author_sort | Chia-wei Yeh |
| collection | DOAJ |
| description | Abstract Asthma is a common disease occurring worldwide. The clinical treatment of asthma is constantly revised and updated; however, it is associated with side effects. Our previous in vitro and ex vivo studies found that oligo-fucoidan can improve allergic immune responses and reduce airway inflammation. The purpose of this clinical trial was to investigate the effects of oligo-fucoidan on the immune status, inflammatory response, and pulmonary function of patients with asthma. Twenty asthmatic patients were randomly divided into two groups: (1) control group: receiving regular asthma treatment and supplementation with placebo; (2) fucoidan group: receiving regular asthma treatment and supplementation with oligo-fucoidan. Pulmonary function tests, the "Asthma Control Questionnaire" survey, biochemical data, inflammatory factors, and immune cell subtypes were detected. During treatment, the levels of WBC (p = 0.038) and creatinine (p = 0.012 and p = 0.008 at 12th and 24th weeks) were significantly decreased in the fucoidan group. Lung function (FEV1/FVC pr) significantly increased in the fucoidan group (p = 0.046). Regarding the proportion of immune cells, the level of IFN+ and CD4+IFN+cells in the fucoidan group was significantly increased during the treatment period (P < 0.05), while the proportions of CD3+CD4+ cells (p = 0.048) and CD3+CD8+ cells (p = 0.009) in the fucoidan group were significantly decreased during the treatment period. Regarding cytokines, the level of interleukin-8 (IL-8) was also significantly reduced in the fucoidan group during the treatment period. |
| first_indexed | 2024-04-12T01:23:34Z |
| format | Article |
| id | doaj.art-d9f22e6fa4474dd2b51522f6ba7894bb |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-12T01:23:34Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-d9f22e6fa4474dd2b51522f6ba7894bb2022-12-22T03:53:43ZengNature PortfolioScientific Reports2045-23222022-10-011211810.1038/s41598-022-21527-3Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trialChia-wei Yeh0Chia-Ju Shih1Tu-Chen Liu2Ya-ling Chiou3Master Program of Biomedical Nutrition Program, Department of Nutrition, Hungkuang UniversityMaster Program of Biomedical Nutrition Program, Department of Nutrition, Hungkuang UniversityDepartment of Chest Medicine, Cheng-Ching General HospitalMaster Program of Biomedical Nutrition Program, Department of Nutrition, Hungkuang UniversityAbstract Asthma is a common disease occurring worldwide. The clinical treatment of asthma is constantly revised and updated; however, it is associated with side effects. Our previous in vitro and ex vivo studies found that oligo-fucoidan can improve allergic immune responses and reduce airway inflammation. The purpose of this clinical trial was to investigate the effects of oligo-fucoidan on the immune status, inflammatory response, and pulmonary function of patients with asthma. Twenty asthmatic patients were randomly divided into two groups: (1) control group: receiving regular asthma treatment and supplementation with placebo; (2) fucoidan group: receiving regular asthma treatment and supplementation with oligo-fucoidan. Pulmonary function tests, the "Asthma Control Questionnaire" survey, biochemical data, inflammatory factors, and immune cell subtypes were detected. During treatment, the levels of WBC (p = 0.038) and creatinine (p = 0.012 and p = 0.008 at 12th and 24th weeks) were significantly decreased in the fucoidan group. Lung function (FEV1/FVC pr) significantly increased in the fucoidan group (p = 0.046). Regarding the proportion of immune cells, the level of IFN+ and CD4+IFN+cells in the fucoidan group was significantly increased during the treatment period (P < 0.05), while the proportions of CD3+CD4+ cells (p = 0.048) and CD3+CD8+ cells (p = 0.009) in the fucoidan group were significantly decreased during the treatment period. Regarding cytokines, the level of interleukin-8 (IL-8) was also significantly reduced in the fucoidan group during the treatment period.https://doi.org/10.1038/s41598-022-21527-3 |
| spellingShingle | Chia-wei Yeh Chia-Ju Shih Tu-Chen Liu Ya-ling Chiou Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial Scientific Reports |
| title | Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial |
| title_full | Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial |
| title_fullStr | Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial |
| title_full_unstemmed | Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial |
| title_short | Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial |
| title_sort | effects of oligo fucoidan on the immune response inflammatory status and pulmonary function in patients with asthma a randomized double blind placebo controlled trial |
| url | https://doi.org/10.1038/s41598-022-21527-3 |
| work_keys_str_mv | AT chiaweiyeh effectsofoligofucoidanontheimmuneresponseinflammatorystatusandpulmonaryfunctioninpatientswithasthmaarandomizeddoubleblindplacebocontrolledtrial AT chiajushih effectsofoligofucoidanontheimmuneresponseinflammatorystatusandpulmonaryfunctioninpatientswithasthmaarandomizeddoubleblindplacebocontrolledtrial AT tuchenliu effectsofoligofucoidanontheimmuneresponseinflammatorystatusandpulmonaryfunctioninpatientswithasthmaarandomizeddoubleblindplacebocontrolledtrial AT yalingchiou effectsofoligofucoidanontheimmuneresponseinflammatorystatusandpulmonaryfunctioninpatientswithasthmaarandomizeddoubleblindplacebocontrolledtrial |